To see the other types of publications on this topic, follow the link: Cml pfd.
Journal articles on the topic 'Cml pfd'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Cml pfd.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Abbas, Waseem, Zubair Mehmood, and Munkyo Seo. "A V-Band Phase-Locked Loop with a Novel Phase-Frequency Detector in 65 nm CMOS." Electronics 9, no. 9 (September 13, 2020): 1502. http://dx.doi.org/10.3390/electronics9091502.
Full textAbstract:
A 65–67 GHz phase-locked loop (PLL) with a novel low power phase-frequency detector (PFD) in 65 nm LP CMOS is presented. The PLL consists of a V-band voltage-controlled oscillator (VCO), a divide-by-two injection-locked frequency divider (ILFD), and a current-mode logic (CML) divider chain. A charge pump (CP) and a 2nd-order loop filter are used with PFD for VCO tuning. The PFD is implemented with 16 transistors with dead-zone-free capability. The measured locking range of the PLL is from 65.15 to 67.4 GHz, with −11.5 dBm measured output power at 66.05 GHz while consuming 88 mW. The measured phase noise at 1 MHz offset is −84.43 dBc/Hz. The chip area of the PLL is 0.84 mm2 including probing pads. The proposed PLL can be utilized as a frequency synthesizer for carrier signal generation in IEEE 802.11ad standard high data rate transceiver circuits.
2
Gunes, Adalet Meral, Frédéric Millot, Krzysztof Kalwak, Birgitte Lausen, Petr Sedlacek, Birgitte Versluijs, Michael Dworzak, Barbara De Moerloose, and Meinolf Suttorp. "Features and Outcome of Chronic Myeloid Leukemia (CML) at Very Young Age: Data from the International Pediatric CML Registry (I-CML-Ped Study)." Blood 132, Supplement 1 (November 29, 2018): 1748. http://dx.doi.org/10.1182/blood-2018-99-112905.
Full textAbstract:
Abstract Introduction: CML is rare in the first two decades of life comprising only 3% of pediatric and adolescent leukemias. The overall annual incidence is approximately 1 per million children and adolescents and it increases with age (median: 12 yrs, range: 1-18) resulting in an extreme rarity of children affected in the first years of life. Data regarding the clinicopathologic characteristics and response to therapy of childhood CML diagnosed at age <3 years has not been reported yet. Aims and objectives: We studied the epidemiologic and clinical features of patients(pts) with CML <3 years of age and evaluated treatment and long term outcome. Material and Methods: Data from pediatric CML pts (age at diagnosis 0-18 yrs) registered from 2010 until 2017 into the International Pediatric CML Registry (Poitiers, France) under the umbrella of the I-BFM Study Group were retrospectively analyzed. Characteristics and treatment outcome of pts <3 yrs at diagnosis were evaluated from standardized forms. Results: 22/479 pts (4.6%, ratio male/female: 14/8) were enrolled with a median age of 22 months (10-34) and a median weight and height were 9.3 kg (8.1-15.5) and 78 cm (73-98), respectively. The median time period from the first symptoms until final diagnosis was 21 days (2-182). Median spleen size was 12 cm (2-20) and median liver size was 3 cm (2-6) below the costal margins. Major complains and symptoms comprised asthenia (30%), fever (30%), abdominal pain (20%), extramedullary signs (14%), hemorrhage (5%), and weight loss (5%). Median WBC, Hb and platelet counts were 154 600/µl (23 000-892 000), 8.7 g/dl (5,6-11,5) and 311 000/µl (51 000-1 820 000), respectively. All pts underwent BM aspiration but, BM biopsy was performed only in 8/22 children. Philadelphia chromosome and BCR-ABL1 gene rearrangement were detected by cytogenetic and/or molecular techniques (FISH and RQ-PCR). In only 2 (9%) children, additional chromosomal abnormalities were detected by cytogenetics classifying one patient in accelerated phase. Overall 19/22 (86%) children were diagnosed in chronic phase and the remaining 3 pts were in advanced phase (CML-AP: n= 2, CML-BP: n= 1). Median follow-up of the cohort was 78 months (7-196). Treatment: 21/22 pts initially received imatinib at the recommended dose of 260-300 mg/sqm/day while one child received IFN + ARA-C. Imatinib was changed to either dasatinib (n= 5) or nilotinib (n= 1) in 6 children (29%). Thus, 15 pts continued on imatinib. During follow-up, 9/22 (41%) pts underwent HSCT including 2 pts after switching to dasatinib. Molecular response: Major molecular response (MR) was achieved in 10/21 (48%) children on TKI. One child (1/21) on TKI was not followed for MR, but he developed complete cytogenetic remission 4 mo after imatinib treatment. The remaining cohort (6/22; 27%) is alive on TKI without major MR with a median follow-up of 77 m (7-186) and 5/22 (23%) achieved complete MR following HSCT. Adverse effects (AE): 194 AE episodes were reported in 18/22 (82%) pts. Most frequently observed AEs were hematologic (20%), gastrointestinal (16%), infectious (14%), musculoskeletal (14%), skin (12%), metabolic (6%), and HSCT-related (GvHD, 5%). Less frequently AEs comprised psychological (3%), edema (3%), tooth development delay (2%), allergic (2%), neurologic (PRESS syndrome,1%), and renal colic (1%). At last follow up, assessment of puberty status revealed that the majority of children were in Tanner stage 1 or 2 (17/22, 77%). Among these, 7 were >10 years old and showed puberty delay, while pubertal development was normal in the remaining 5/22 pts. Data on growth and development was available in 15/22 (68%) children. The majority had experienced decline of height (93%) and weight (73%). In 4 (27%) and 2 (13%) pts, respectively, measurements were found below the 3rd-10th percentiles. Delta z-score analysis for height and weight revealed that the z-scores in total 3 pts were below -2. Survival: 21/22 (95%) children are alive while one patient died of GvHD. Two pts' last molecular status is unknown. 7/19 pts (37%) are in molecular CR following HSCT and the other 12/19 (63%) are still on TKI. Out of these, 3/12 pts achieved durable CMR with TKI (PCR negative) while the remaining 9/12 pts show either fluctuating (n= 3 ) or no major MR (n= 6). Conclusion: This report demonstrates for the first time the efficacy and long term side effects of upfront imatinib in the so far largest cohort of children with CML diagnosed at very young age. Disclosures Kalwak: Sanofi: Other: travel grants; medac: Other: travel grants.
3
Millot, Frédéric, Meinolf Suttorp, Joelle Guilhot, Pietr Sedlacek, Evelina S. De Bont, Chi Kong Li, Krzysztof Kalwak, et al. "The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results." Blood 120, no. 21 (November 16, 2012): 3741. http://dx.doi.org/10.1182/blood.v120.21.3741.3741.
Full textAbstract:
Abstract Abstract 3741 Background: CML is a very rare disease in children and adolescents accounting for less than 5% of all CML cases. Only scant data is available regarding epidemiology, presenting features and outcome of CML in this age range. Aims: An international registry (I-CML-Ped Study) was established to assess epidemiology, management and outcome of CML in the pediatric population. The main objectives of the study are the following: i) to describe the clinical and biological characteristics of CML in a large cohort of patients less than 18 years of age, ii) to identify prognostic factors in this age-group in order to optimize individual treatment choices iii) to determine side effects and long term effects of treatments, mainly the tyrosine kinase inhibitor effect, on growth and development of a pediatric cohort. Methods: All national pediatric study groups were invited to participate. All newly diagnosed children and adolescents less than 18 years diagnosed later than January 2000 has to be notified and collection of the follow- up data is planned. The study is strictly observational and informed consent from the patient and/or the legal guardians is required for enrollment. The study was started in January 2011. Results: As of July 2012, 200 patients (pts) from 9 countries have been registered. There was a male preponderance (59%). The median age at diagnosis was 11.6 years (range, 8 months −18 years); 8% of the patients were younger than 4 years. Clinical and biological data at initial diagnosis so far is available in 150 pts. At time of diagnosis 92% were in chronic phase, 6% in accelerated phase and 2% in blastic phase according to the European Leukemia Net criteria. The Sokal risk group distribution was: 13% low, 33% intermediate and 55% high risk. The majority of the patients showed a Lansky score of 100 (67%) or 90 (16%). Splenomegaly was present in 76% of patients. The median of the spleen size below the costal margin was 8 cm (range: 0 to 25 cm). The median of the leukocyte count was 250×109/L (range: 5 to 1037). Additional chromosomal abnormalities in Ph-positive cells were observed in 2.3 % of the patients. The BCR-ABL transcript type was available in 100 patients: b3a2 51%, b2a2 40%, b3a2 plus b2a2 7% and b2a3 2%. The median follow-up time is 28 months (range, 2–138). Five deaths were recorded. The estimated overall survival rate at 42 months is 97% (CI 95%, 91–99). Forty seven (63%) of 75 assessable patients for cytogenetic response achieved complete cytogenetic response 12 months after the start of the treatment (imatinib: 43 pts, switch to dasatinib after imatinib failure: 3 pts, interferon + cytosine arabinoside: 1pt). Data collection regarding molecular assessment is ongoing and will be presented. Conclusion: This is the largest study reporting on children and adolescents with CML. The data indicates that children and adolescents with CML presented with clinical and biological differences compared to adult patients with CML. Whether these differences translate into a different outcome still remains to be determined. Acknowledgment: The I-CML Ped study is supported by an unrestricted grant from Novartis Pharmaceutical Company Disclosures: No relevant conflicts of interest to declare.
4
Park, Boumyoung, Hyunseop Lee, Kihyun Park, Heondeok Seo, Haedo Jeong, Hoyoun Kim, and Hyoungjae Kim. "Fixed Abrasive Pad with Self-conditioning in CMP Process." Journal of the Korean Institute of Electrical and Electronic Material Engineers 18, no. 4 (April 1, 2005): 321–26. http://dx.doi.org/10.4313/jkem.2005.18.4.321.
Full text
5
Millot, Frédéric, Joelle Guilhot, Meinolf Suttorp, Petr Sedlacek, Eveline S. J. M. de Bont, Chi Kong Li, Krzysztof Kalwak, et al. "The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration." Blood 124, no. 21 (December 6, 2014): 521. http://dx.doi.org/10.1182/blood.v124.21.521.521.
Full textAbstract:
Abstract Aims: An international registry (I-CML-Ped Study)was established to assess epidemiology, management and outcome of CML in the pediatric population. Methods: All national pediatric study groups were invited to include newly diagnosed children and adolescents less than 18 years with CML diagnosed later than January 2000. Results: Since January 2011, 351 patients from 12 countries have been registered. Clinical and biological data at initial diagnosis are available in 278 patients.There was a male preponderance (57%). The median age at diagnosis was 12.4 years (range, 9 months -17.5 years); 6% of the patients were younger than 4 years. At time of diagnosis 92% of the children were in chronic phase, 8% in accelerated phase and 1% in blastic phase according to the European Leukemia Net criteria. The Sokal risk group distribution was: 18% low, 31% intermediate and 51% high risk. The majority of the patients showed a Lansky score of 100 (59%) or 90 (21%). Splenomegaly was present in 76% of patients. The median of the spleen size below the costal margin was 11 cm (range: 1 to 25 cm). The median of the leukocyte count was 235x109/L (range: 5 to 1038). Additional chromosomal abnormalities in Ph-positive cells were observed in 6 % of the patients. The BCR-ABL transcript type was available in 227 patients: b3a2 54%, b2a2 38%, b3a2-b2a2 6% and b2a3 2%. The median follow-up time is 39 months (range, 0.5-161). Eight deaths were recorded. The estimated overall survival rate at 60 months is 95% (95%CI 89-97). Irrespective of treatment and follow-up, 124 (73%) of 169 assessable patients for cytogenetic response achieved complete cytogenetic response (CCyR). Exploratory analyses were performed in newly diagnosed patients regarding clinical and biological factors influencing the achievement of CCyR 12 months after starting imatinib. In univariate analyses, the Eutos score, the spleen size, the hematocrit level, the lymphocyte count and immature cells in peripheral blood, the percentage of granulocytes and monocytes in the marrow were identified as potential prognostic factors. However, only the percentage of the granulocytes in the marrow was identified as independent factor of achievement of CCyR at 12 months in multivariate analysis. Data collection and quality control regarding molecular assessment are ongoing. Conclusion: The data indicates that children and adolescents with CML presented with clinical and biological differences compared to adult patients with CML. Identification of prognostic factors is needed to optimize the strategy in the pediatric population. Acknowledgment: The I-CML Ped study is supported by an unrestricted grant from Novartis Pharmaceutical Company Disclosures No relevant conflicts of interest to declare.
6
Pak, Byeongjun, Dasol Lee, Seonho Jeong, Hyunjin Kim, and Haedo Jeong. "Finite Element Analysis on Dynamic Viscoelasticity of CMP Polishing Pad." Journal of the Korean Society for Precision Engineering 36, no. 2 (February 1, 2019): 177–81. http://dx.doi.org/10.7736/kspe.2019.36.2.177.
Full text
7
Park, Ki-Hyun, Hyoung-Jae Kim, Jae-young Choi, Heon-deok Seo, and Hae-do Jeong. "The Effects of Groove Dimensions of Pad on CMP Characteristics." Transactions of the Korean Society of Mechanical Engineers A 29, no. 3 (March 1, 2005): 432–38. http://dx.doi.org/10.3795/ksme-a.2005.29.3.432.
Full text
8
Choi, Gwon-Woo, Nam-Hoon Kim, Yong-Jin Seo, and Woo-Sun Lee. "CMP Properties of Oxide Film with Various Pad Conditioning Temperatures." Journal of the Korean Institute of Electrical and Electronic Material Engineers 18, no. 4 (April 1, 2005): 297–302. http://dx.doi.org/10.4313/jkem.2005.18.4.297.
Full text
9
EGAMI, Kazutaka, Syuhei KUROKAWA, Toshiro DOI, Osamu OHMSHI, Midhio UNEDA, and Kazunori KADOMURA. "907 Condition of Grain on CMP Conditioner and Pad Surface Analysis." Proceedings of Conference of Kyushu Branch 2012.65 (2012): 319–20. http://dx.doi.org/10.1299/jsmekyushu.2012.65.319.
Full text
10
de Cortazar, Victor Garcia, and Gabino Reginato. "Yield, PFD Interception, and Crop Load Relationships in `Royal Gala' Apples." HortScience 41, no. 4 (July 2006): 1010A—1010. http://dx.doi.org/10.21273/hortsci.41.4.1010a.
Full textAbstract:
Three different parameters were tested to estimate yield in `Royal Gala' apples. These are: a) parameters related to crop load—fruits per tree, fruits per cm2 of branch cross-sectional area, and fruits per hectare; b) parameters related with PFD interception: average fraction of PFD intercepted, total PFD intercepted during the season; and c) combination of the parameters a) and b). The data set was composed of measurements of PFD interception once a month and of yield components on various commercial apple orchards of the variety `Royal Gala' in the central zone of Chile between 2003 and 2006. The orchards were managed for high production, but there were differences of plantation distance, age, and size between them. Also, inside the orchard there were differences between trees. For the trees studied, there were variations of a factor of 10 for crop load, branch cross-sectional area, and tree size estimated as fractional interception of PFD at the beginning of the season. In spite of the big differences between trees, simple equations were fitted between yield and load parameters with coefficients of determination >0.95. Research funded by FONDECYT-Chile grant 1930695.
11
Greenbaum, Lior, Idit Maya, Lena Sagi-Dain, Rivka Sukenik-Halevy, Michal Berkenstadt, Hagith Yonath, Shlomit Rienstein, Adel Shalata, Eldad Katorza, and Amihood Singer. "Chromosomal Microarray Analysis in Pregnancies With Corpus Callosum or Posterior Fossa Anomalies." Neurology Genetics 7, no. 3 (May 28, 2021): e585. http://dx.doi.org/10.1212/nxg.0000000000000585.
Full textAbstract:
ObjectiveWe investigated the detection rate of clinically significant chromosomal microarray analysis (CMA) results in pregnancies with sonographic diagnosis of fetal corpus callosum anomalies (CCA) or posterior fossa anomalies (PFA).MethodsAll CMA tests in pregnancies with CCA or PFA performed between January 2015 and June 2020 were retrospectively evaluated from the Israeli Ministry of Health database. The rate of CMA with clinically significant (pathogenic or likely pathogenic) findings was calculated and compared to a local Israeli cohort of 5,541 pregnancies with normal ultrasound.ResultsOne hundred eighty-two pregnancies were enrolled: 102 cases with CCA and 89 with PFA (9 cases had both). Clinically significant CMA results were found in 7/102 of CCA (6.9%) and in 7/89 of PFA (7.9%) cases. The CMA detection rate in pregnancies with isolated CCA (2/57, 3.5%) or PFA (2/50, 4.0%) was lower than in nonisolated cases, including additional CNS and/or extra-CNS sonographic anomalies (CCA-5/45, 11.1%; PFA-5/39, 12.8%), but this was not statistically significant. However, the rate among pregnancies that had extra-CNS anomalies, with or without additional CNS involvement (CCA-5/24, 20.8%; PFA-5/29, 17.2%), was significantly higher compared to all other cases (p = 0.0075 for CCA; p = 0.035 for PFA). Risk of CMA with clinically significant results for all and nonisolated CCA or PFA pregnancies was higher compared to the background risk reported in the control cohort (p < 0.001), but was not significant for isolated cases.ConclusionsOur findings suggest that CMA testing is beneficial for the genetic workup of pregnancies with CCA or PFA, and is probably most informative when additional extra-CNS anomalies are observed.
12
AKAMA, Taro, Syuhei KUROKAWA, Toshiro DOI, Osamu OHNISHI, Yoji UMEZAKI, Yoji MATSUKAWA, and Kazunori KADOMURA. "K25 Effects of Pad Conditioning on W-CMP." Proceedings of Conference of Kyushu Branch 2011.64 (2011): 399–400. http://dx.doi.org/10.1299/jsmekyushu.2011.64.399.
Full text
13
Takahashi, Naoaki, Keiichi Kimura, and Khajornrungruan Panart. "K14 Study of Fabricated Micro Pattern Pad using CMP MEMS Technology : Characteristic Evaluation of Micro Pattern Pad Surface." Proceedings of Conference of Kyushu Branch 2008.61 (2008): 355–56. http://dx.doi.org/10.1299/jsmekyushu.2008.61.355.
Full text
14
Miyata, Tatsunori, and Laura E. Nagy. "Programmed cell death in alcohol-associated liver disease." Clinical and Molecular Hepatology 26, no. 4 (October 1, 2020): 618–25. http://dx.doi.org/10.3350/cmh.2020.0142.
Full textAbstract:
Alcohol-associated liver disease (ALD), which ranges from mild disease to alcohol-associated hepatitis and cirrhosis, is the most prevalent type of chronic liver disease and a leading cause of morbidity and mortality worldwide. Accumulating evidence reveals that programmed cell death (PCD) plays a crucial role in progression of ALD involving crosstalk between hepatocytes and immune cells. Multiple pathways of PCD, including apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis, are reported in ALD. Interestingly, PCD pathways are intimately linked and interdependent, making it difficult to therapeutically target a single pathway. This review clarifies the multiple types of PCD occurring in liver and focuses on crosstalk between hepatocytes and innate immune cells in ALD.
15
Albahar, Marwan, Mohammed Thanoon, Monaj Alzilai, Alaa Alrehily, Munirah Alfaar, Maimoona Algamdi, and Norah Alassaf. "Toward Robust Classifiers for PDF Malware Detection." Computers, Materials & Continua 69, no. 2 (2021): 2181–202. http://dx.doi.org/10.32604/cmc.2021.018260.
Full text
16
Ruiz, Maria Cristina, Manuel Portero–Otín, Reinald Pamplona, Jesús R. Requena, Joan Prat, Maria Antonieta Lafarga, Mercè Borràs, and Maria Josep Bellmunt. "Chemical and Immunological Characterization of Oxidative Nonenzymatic Protein Modifications in Dialysis Fluids." Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 23, no. 1 (January 2003): 23–32. http://dx.doi.org/10.1177/089686080302300103.
Full textAbstract:
← Background Glucose degradation products (GDP) in dialysis fluids may induce nonenzymatic protein modifications, the chemical nature and biological properties of which should be better defined. ← Aims To characterize nonenzymatic protein modifications present in glucose-based peritoneal dialysis fluids (PDF) and to evaluate the relationship between concentrations of GDP and the derived nonenzymatic modifications, and the potential of PDF for generating these modifications in vitro. ← Methods The presence, distribution, and content of several nonenzymatic protein modifications in PDF were evaluated by immunological methods, by HPLC, and by gas chromatography-mass spectrometry (GC/MS). Peritoneal dialysis fluid-induced oxidative stress in cells was evaluated by flow cytometry. The potential of PDF for generating oxidative and glycoxidative modifications was examined by immunological and cross-linking analyses. ← Results The albumin present in PDF is modified by carboxymethyllysine (CML). GC/MS analyses of PDF proteins confirmed the presence of CML and demonstrated the occurrence of carboxyethyllysine, malondialdehyde lysine, and oxidation-derived semialdehydes. Furthermore, their concentrations in PDF proteins were significantly higher than those in plasma proteins (in all cases, p < 0.02). The concentration of pyrraline, a non-oxidative advanced glycation end-product, increased with dwell time up to 6 hours ( p < 0.03). The PDF induced cellular free-radical production, which was partially inhibited by the Maillard reaction inhibitor aminoguanidine ( p < 0.001). The potential to generate oxidative and glycoxidative modifications demonstrated an inverse relationship with dwell time ( p < 0.05). The PDF was able to induce collagen cross-linking in a close relationship with GDP concentration. ← Conclusions ( 1 ) PDF contains non-oxidative and several oxidative nonenzymatic protein modifications in higher concentrations than plasma. ( 2 ) Peritoneal dialysis fluid induces oxidative stress in vitro, which can be partially inhibited by aminoguanidine. ( 3 ) These properties are directly related to GDP concentration. ( 4 ) Peritoneal dialysis fluid is able to generate glycoxidative and oxidative damage to proteins in vitro in a dwell-time dependent fashion.
17
Jeong, Kyeongwoo, Seonho Jeong, Somin Shin, Jinuk Choi, and Haedo Jeong. "Identification of the Break-In Mechanism by Asperity Deformation of CMP Pad." Journal of the Korean Society for Precision Engineering 38, no. 2 (February 1, 2021): 87–95. http://dx.doi.org/10.7736/jkspe.020.082.
Full text
18
Baldomero, Helen, Mahmoud Aljurf, Luis Fernando Bouzas, Alois Gratwohl, Yoshihisa Kodera, Jeff H. Lipton, J. Alejandro Madrigal, et al. "Global Trends in Hematopoietic Cell Transplantation." Blood 120, no. 21 (November 16, 2012): 3143. http://dx.doi.org/10.1182/blood.v120.21.3143.3143.
Full textAbstract:
Abstract Abstract 3143 Hematopoietic cell transplantation (HCT) is the treatment of choice for many patients with malignant and non-malignant disorders. Transplant practices have evolved allowing patients previously not otherwise candidates to receive this procedure. Activity surveys and registries play an essential role in the success of HCT, by tracking activities, identifying areas of need and through clinical research to continue improving patient outcome. Because of the need of matched donors, ethnic characteristics and legal requirements HCT has acquired a global dimension. In the current analysis the Worldwide Blood and Marrow Transplantation network (WBMT) reports the global activities, indications and trends for the years 2006 to 2008. The survey consisted of activities reported to the WBMT from international societies members (EBMT, CIBMTR, APBMT, EMBMT, ABMTRR), national registries (SBTMO) and also directly from transplant centers in regions were no societies are established. Annual transplant center specific activities were from 1327 transplant centers in 71 countries in 2006. The number of participating centers increased to 1382 and 1407 in 2007 and 2008, respectively. Annual number of transplants steadily increased from 46,563 in 2006 to 48,709 and 51,536 in 2007 and 2008. When analyzing the median number of transplants/year performed at each center the corresponding annual activity was 38 (range 3–180), 46 (3–421) and 48 (1–389), suggesting that the increment in transplant activity is not only related to higher number of reporting centers. The highest increase in total HCT over two years was observed in the Asia Pacific region (38.6%) followed by the East Mediterranean region (19.4%), Europe (5.6%) and the U.S. (4.5%). An absolute increase of autologous and allogeneic was observed over the three year period with more autologous (55%) than allogeneic (45%) HCT reported, however the increase was less in autologous (+5.0%) when compared to allogeneic (+17.9%). Among indications for allogeneic HCT, acute leukemias (AML +23%; ALL +27%), myelodysplasia (MDS +26%), chronic lymphocytic leukemia (CLL +24.6%) nonmalignant diseases (NMD +23.6%) and bone marrow failure disorders (BMF +21.2%) significantly increased during the study period. Slower increase was reported for lymphoproliferative disorders (LPD +6%) and a clear decrease for chronic myelogenous leukemia (CML -17%) and solid tumors (−13.3%). Among autologous HCT indications autoimmune diseases (+24.5%), PCD (+9.8%) and LPD (+7.5%) increased during the period. A negative trend was seen in autologous HCT for solid tumors (−2.4%), ALL (−22.0%), AML (−9.0%), CLL (−52.0%) and CML (−57.1%). These data show the trend and activity for autologous and allogeneic HSCT worldwide. There is a clear increase in activity especially in acute and chronic (except CML) leukemias for allogeneic HST and for autoimmune diseases, LPD and PCD in autologous HCT. Monitoring global transplant practices is an important activity for WBMT in order for capacity planning of HCT donor pool worldwide and to promote the field by expanding access to transplantation at regions in need. Disclosures: No relevant conflicts of interest to declare.
19
KITAMURA, Masashi, Atsunori WATANABE, Syuhei KUROKAWA, Terutake HAYASHI, Hirokuni HIYAMA, Yutaka WADA, and Chikako TAKATOH. "Observational investigation of surface texture in soft type CMP pad." Proceedings of Conference of Kyushu Branch 2017.70 (2017): 905. http://dx.doi.org/10.1299/jsmekyushu.2017.70.905.
Full text
20
Dow, Alan. "Sequential Order under PFA." Canadian Mathematical Bulletin 54, no. 2 (June 1, 2011): 270–76. http://dx.doi.org/10.4153/cmb-2010-099-3.
Full text
21
Shah, Binay K., and Krishna B. Ghimire. "Second Primary Malignancies in Chronic Myeloid Leukemia." Blood 120, no. 21 (November 16, 2012): 4247. http://dx.doi.org/10.1182/blood.v120.21.4247.4247.
Full textAbstract:
Abstract Abstract 4247 Background: Development of second primary cancers among CML patients is not well studied. With improvement in CML survival, long term risks of CML, including second cancers need to be evaluated. This study was conducted to evaluate second primary malignancies in CML patients using data from the US Surveillance, Epidemiology and End Results (SEER) cancer registries. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER*Stat) database: Incidence - SEER 13 Regs Research Data, Nov 2011 Sub, Vintage 2009 Pops (1992–2009) using MP-SIR Session. We compared secondary cancer rate among adult CML patients (older than 20 years of age) during the period 1992 – 2009. We also evaluated the risk of secondary malignancies in pre- (1992–2000) to post- imatinib (2001–2009) eras. We used SEER MP-SIR session and Graph pad scientific software to calculate p value. Results: The total number of CML patients older than 20 years of age, reported during 1992–2009 period was 8,511. There were 4286 and 4225 CML patients in the pre- (1992–2000) and post- (2001–2009) Imatinib era respectively. All site secondary cancer (n=475) incidence was significantly higher among CML patients compared to general population with observed/expected ratio (O/E):1.28, p=< 0.05, an absolute excess risk of 31.39 per 10,000. Similarly, all sites secondary cancer in post-(2001–2009) Imatinib era was significantly higher compared to pre- imatinib era with O/E ratio of 1.50 vs 1.13, p=0.03. Conclusions: This study showed that overall risk of second malignancies among CML patients is higher compared to general population. The risk of second primary malignancies is higher in post- imatinib era. Disclosures: No relevant conflicts of interest to declare.
22
Wallick, D. W., and P. J. Martin. "Separate parasympathetic control of heart rate and atrioventricular conduction of dogs." American Journal of Physiology-Heart and Circulatory Physiology 259, no. 2 (August 1, 1990): H536—H542. http://dx.doi.org/10.1152/ajpheart.1990.259.2.h536.
Full textAbstract:
In open-chest, autonomically decentralized, anesthetized dogs, a brief burst of electrical stimuli was delivered at various time delays to the right pulmonary vein (RPV) fat pad. This fat pad contains parasympathetic ganglia that innervate the sinoatrial (SA) node. Each burst elicited a bimodal increase in the cardiac cycle length (CCL) without eliciting a significant change in atrioventricular conduction time (AVCT). A similar burst was applied to the inferior vena cava-inferior left atrial fat pad. This fat pad contains nerves that innervate the AV node. This latter stimulation elicited a bimodal increase in AVCT without eliciting any change in the CCL. When the cervical vagi were stimulated in a similar manner, a bimodal increase in the CCL was elicited that was similar to the response we observed when the RPV fat pad was stimulated. In contrast, the dromotropic response was quite variable. In conclusion, we could, for the most part, elicit selective parasympathetic control of either the SA or the AV node, respectively.
23
Borges, Kellen Christina Malheiros, Jussara Rocha Ferreira, and Leonardo Ferreira Caixeta. "The prefrontal areas and cerebral hemispheres of the neotropical Cebus apella and their correlations with cognitive processes." Dementia & Neuropsychologia 4, no. 3 (September 2010): 181–87. http://dx.doi.org/10.1590/s1980-57642010dn40300006.
Full textAbstract:
Abstract The organization of the prefrontal cortex can hold important clues to understanding its functioning. The Cebus apella present cerebral particularities and behavioral and cognitive flexibility, possessing abilities that demonstrate an overlap with those of big primates. Objectives: To provide evidence of correlations between anatomical particularities of the brain areas analyzed and some cognitive abilities previously described in these simians. Methods: The relative size of the cerebral hemispheres and prefrontal areas (PFA) were measured using a Universal caliper, in 24 hemispheres of C. apella fixed with 10% formaldehyde and kept in 70% alcoholic solution. Results: Data gathered allowed the calculation of the approximate volume (cm3) of the areas under study: right antimere 35.2 cm3 (±5.3), left antimere 31.3 cm3 (±5.4) and of the left PFA 6.0 cm3 (±1.5) and right PFA 6.9 cm3 (±1.7). Conclusions: We concluded that the PFA represents about 20% of the cerebral volume of this primate. No significant differences were found in the antimeres in terms of volume and area of the hemispheres and likewise for the PFA. These animals have a proportionally bigger brain than that of other neotropical primates in the literature. This allows us to infer that the frontal lobe of C. apella is also larger; possibly related to its maturity and developed cognitive functions indicative of the culture transfers characteristic of this species.
24
Millot, Frédéric, Meinolf Suttorp, Stéphanie Ragot, Guy Leverger, Jean-Hugues Dalle, Birgitta Versluijs, Birgitte Lausen, and Marina Borisevich. "Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study." Blood 136, Supplement 1 (November 5, 2020): 53–54. http://dx.doi.org/10.1182/blood-2020-135844.
Full textAbstract:
Background: Imatinib, a tyrosine kinase inhibitor (TKI) is currently proposed as first line therapy in children with chronic myeloid leukemia (CML) in chronic phase (CP). Studies in adults with CML demonstrated that 40 to 50% of patients with prolonged deep molecular response under TKI could discontinue TKI permanently without molecular relapse. However, data regarding TKI discontinuation in children with CML are limited. Methods: Using the ELN criteria we identified in the International Registry of Childhood Chronic Myeloid Leukemia 18 patients less than 18 years of age at diagnosis with CML in CP exhibiting under imatinib treatment sustained deep molecular response >MR4.0 (DMR) for ≥ 2 years and then discontinued the TKI. We retrospectively analyzed outcome of these patients and treatment-free remission rate (TFR) at various time points. Treatment with imatinib was resumed in case of molecular relapse defined as loss of major molecular response (MMR). Results: There were 11 boys and 7 girls. From diagnosis in CP until TKI discontinuation the 18 children showed no progression, resistance, warning or suboptimal response or switch to another TKI before discontinuation. Median age at diagnosis of CML was 11.9 years (range, 2.3 to 15.8 years) and median age at discontinuation of TKI was 16 years (range, 9 to 24 years). Median overall follow-up from diagnosis of CML was 107 months (range, 67-209 months). DMR was achieved after a median time of 12 months (range, 3 - 50 months) on imatinib. Before discontinuation median treatment duration of imatinib was 73.25 months (range, 32 to 109 months) and median duration of MR4.0 was 46.2 months (range, 23.9 to 98.6 months). Seven patients experienced molecular relapse 4.1 months (range, 1.9-6.4 months) after stopping and restarted imatinib. Two patient resumed imatinib 3.6 and 3.4 months after discontinuation because of increased in transcript level (from 0.001% to 0.01 and 0.012, respectively) but without loss of MMR. The median molecular follow up after discontinuation was 116 months (range, 71 to 209 months) for the patients without molecular relapse. The proportion of patients maintaining molecular free remission was 61% (95% CI, 38%-83%), 56% (95% CI, 33%-79%) and 56% (95% CI, 33%-79%) at 6, 12, and 36 months, respectively (Figure 1). Six of the 7 children who experienced molecular relapse after discontinuation again achieved MR4.0 at median of 4.7 months (range, 2.5-18 months) after restart of imatinib; the remaining patient achieved MMR but not DMR and was switched to Dasatinib. No withdrawal syndrome was observed in this cohort of 18 patients. In univariate analysis, age, sex, Sokal and ELTS scores, imatinib treatment duration before discontinuation and duration of DMR until imatinib discontinuation had no influence on treatment free remission. Conclusion: These data indicate that imatinib could be safely discontinued in children younger than 18 years of age at diagnosis of CML with sustained MR4.0 for at least 2 years under imatinib. Larger studies of TKI discontinuation in children with CML are needed in order to identify factors predicting treatment free remission. Disclosures Dalle: Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Medac: Consultancy, Honoraria; Orchard: Consultancy, Honoraria; Bellicum: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; bluebird bio: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi-Genzyme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Honoraria; AbbVie Pharmacyclics: Membership on an entity's Board of Directors or advisory committees.
25
Cosson, Adrien, Elise Chapiro, Jérome Lambert, Hong-Anh Cung, Caroline Algrin, Frédérik Damm, Clémentine Gabillaud, et al. "The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia." Blood 126, no. 23 (December 3, 2015): 492. http://dx.doi.org/10.1182/blood.v126.23.492.492.
Full textAbstract:
Abstract Introduction: CLL is a heterogeneous disease in terms of response to treatment, with some patients reaching complete and prolonged remissions, while others relapsing early and requiring several lines of treatments. This highly variable course is partly explained by the existence of a heterogenic panel of genetic alterations (mutations, chromosomal abnormalities) that allow the development of drug-resistant aggressive CLL subclones. Therefore, a functional characterization of the cytogenetic alterations associated to CLL drug resistance may provide new means of improving the current therapeutic strategies. We and others have already reported that the gain of 2p (2p+) is recurrent in CLL. However, the candidate gained gene(s) on the 2p remain to be identified. Previously data: we have observed that the 2p gain is frequent in previously untreated CLL Binet stages B/C (21/132, 15.9%), and is associated with bad prognostic factors, such as 11q deletion (p=0.0008) and unmutated IGHV (p=0.02). Using a SNP-array approach, we have identified a minimally gained region of 1.28Mb on 2p16.1-15. This region included the gene CRM1/XPO1 (Chromosome Region Maintenance 1/Exportin-1), a gene also recurrently mutated in CLL. A qPCR assessment confirmed that XPO1 was overexpressed in the 2p+/CLL patients (1.4-fold increase compared to 2p-/CLL; p=0.02). The objective of our work was to identify the potential role of XPO1 in CLL drug resistance by using the selective XPO1 inhibitor Selinexor (KPT-330, provided by Karyopharm Therapeutics), which is currently in Phase II human clinical trials in hematological and solid cancers. Methods: We have analyzed 36 2p+/CLL and we have searched for XPO1 mutations in 436 CLL samples. CLL drug resistance associated to XPO1 overexpression/mutation was assessed by measuring the rate of programmed cell death (PCD) on cells from 2p- and wildtype (wt) XPO1/CLL (n=20), 2p+/XPO1 wt/CLL (n=8) and on XPO1 mut/CLL (n=6). After 24 hours treatment with Fludarabin + Cyclophosphamid + Rituximab (FCR), Ibrutinib (Ibru), Idelalisib + Rituximab (Ide+R) and Selinexor, cells were stained with Annexin-V and propidium iodide and PCD was assessed by flow cytometry. KPT-301 was used as a negative control. For the inhibition assay, the inhibitor Q-VD-Oph was added 30 min before inducing cell death. Mitochondrial membrane depolarisation was assessed using tetramethyllrhodamine ethyl ester probe and flow cytometry analysis. Results: (i) Using a FISH approach, we fully confirmed the gain of XPO1 in 2p+/CLL samples. Additionally, we found that the XPO1 gain was often subclonal, suggesting that it tends to arise late in leukemic development. Longitudinal FISH analyses, performed on 8 2p+/CLL-treated patients, showed a similar or increasing percentage of cells carrying XPO1 gain at relapse, when compared to diagnosis; (ii) XPO1 was mutated in 23/436 (5.3%) CLL and in 2/30 (6.7%) 2p+/CLL; (iii) Selinexor induced PCD in 2p-/XPO1 wt/CLL (35% of PCD). The results were similar in all tested CLL, independently of prognostic factors (del13q, tri12, del11q, del17p, IGHV status), while sparing the non leukemic cells from patients or B cells from healthy donors; (iv) Selinexor induced CLL PCD through a caspase-dependant apoptotic pathway, as evidenced by inhibition of cell death by Q-VD-Oph, and cleavage of the caspase-3. Selinexor also induced mitochondrial depolarization and was associated with upregulation and activation of the pro-apopototic Bax protein; (v) XPO1 mut/CLL were significantly resistant to PCD induced by Selinexor (p=0.003). In contrast, the mutations in XPO1 had no effect in FCR and Ibru PCD induction; (vi) 2p+/CLL cells were resistant to PCD induced by all tested drugs: FCR (p=0.01), Ibru (p=0.003), Ide+R (p=0.004) and Selinexor (p=0.0001). Conclusion: Our data show that 2p+/CLL is associated to FCR, Ibru and Ide+R drug resistance. Strikingly, Selinexor, a new XPO1 inhibitor, is unable to induce PCD in 2p+ and/or XPO1 mut CLL, which strongly suggests a key role for XPO1 in the CLL drug resistance associated to the 2p gain. Altogether, our work provide substantial progress in the understanding of the role of XPO1 in CLL drug resistance and suggests that the assessment of the 2p gain and the mutations in XPO1 will be considered before to decide a CLL therapy. As 2p gain could be observed in other B malignancies, it is tempting to extend these recommendations to all Selinexor treatments. Disclosures Choquet: Janssen: Consultancy; Roche: Consultancy. Leblond:Janssen: Consultancy, Honoraria, Speakers Bureau; GSK: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Speakers Bureau; Mundipharma: Honoraria.
26
Cho, Kee Hyeon, Kee Ahn Lee, Moon Chul Kim, and Joong Mook Yoon. "Numerical Modeling of Planar Flow Casting Process." Solid State Phenomena 116-117 (October 2006): 106–9. http://dx.doi.org/10.4028/www.scientific.net/ssp.116-117.106.
Full textAbstract:
This study sought to examine the effect of various process parameters on the thickness of the amorphous strip produced by Planar Flow Casting (PFC), which is used to solidify molten metals rapidly. The processes were simulated via fully coupled fluid flow, heat transfer, and solidification models. The temperature distribution and velocity profile of melt in the computational domain with given process parameters were investigated according to various melt inlet temperatures, size of gap between nozzle slots, rotating wheel, and ejection pressure. In general, stable shaping of ribbons was obtained given a heat transfer coefficient of 100 cal/cm2/sec/°C. Strip thickness was found to decrease with the pouring temperature of melt. The results evaluated based on the numerical model were verified based on experimentally measured data.
27
YANG, BIAOGUI, and XIMIN LIU. "Complete spacelike CMC hypersurfaces in a Lorentzian space form." Publicationes Mathematicae Debrecen 78, no. 3-4 (April 1, 2011): 513–25. http://dx.doi.org/10.5486/pmd.2011.4476.
Full text
28
Stern, Martin, Liesbeth C. de Wreede, Ronald Brand, Anja van Biezen, Peter Dreger, Mohamad Mohty, Theo M. de Witte, Nicolaus Kröger, and Tapani Ruutu. "Impact of Graft-Versus-Host Disease On Relapse After Allogeneic Hematopoietic Stem Cell Transplantation, an EBMT Megafile Study." Blood 120, no. 21 (November 16, 2012): 469. http://dx.doi.org/10.1182/blood.v120.21.469.469.
Full textAbstract:
Abstract Abstract 469 Background: After allogeneic HSCT, graft-versus-host disease (GvHD) occurs through recognition of minor or major histocompatibility mismatches by donor derived T lymphocytes. The same mechanism also operates in the elimination of residual malignant cells (the graft-versus-leukemia or GvL effect). Earlier studies have already shown reduced relapse risks for patients developing GvHD (Weiden et al, NEJM 1979; Horowitz et al, Blood 1990). In particular, a large study in CML patients (Gratwohl et al, Blood 2002) showed that increasing grades of acute and chronic GvHD are associated with a proportional decrease in relapse risk. Incidence and severity of acute and chronic GvHD might therefore be used as surrogate markers for GvL effects. Transplant procedures have changed significantly since these publications. Increased use of unrelated donors, peripheral blood as stem cell source, and the introduction of reduced intensity conditioning regimens might affect the relationship between GvHD and GvL. Furthermore, previous studies have only analyzed transplants for AML, ALL and CML, the prevailing transplant indications at the time. Today, many patients receive transplants for MDS, plasma cell disorders (PCD) or lymphoma. We hypothesized that comparing the effect GvHD on relapse incidence might provide a useful surrogate marker for the susceptibility of different diseases to allo-immune effects. Methods: We studied 48,111 first allogeneic transplants carried out and reported to EBMT between 1998 and 2007. The impact of GvHD on relapse risk was assessed by including acute and chronic GvHD as time-dependent covariates in Cox models for cause-specific hazards adjusted for patient age, year of transplant, donor type, stem cell source, and type of conditioning regimen. Results: Diseases were CML (N=7,711), AML (14,539), ALL (6,802), MDS/MPN (6,958), lymphoma (N=8,231), or PCD (3,870). Donors were HLA identical family donor (N=28,030), and HLA-identical unrelated donors (N=14,422) or mismatched donors (N=5,659). Stem cell source was bone marrow (N=13,273), peripheral blood (N=34,022), or cord blood (N=816). Conditioning intensity was myeloablative (N=28,843), reduced intensity (15,889) or unknown (N=3,379). 14,764 (31%) of grafts were T-cell depleted. Incidence of grade I-IV acute GvHD was 49%, that of grade II-IV acute GvHD 30%. Limited chronic GvHD was diagnosed in 17% and extensive chronic GvHD in 20% of patients. Incidence of disease relapse was 22%, 28%, and 31% at 1, 2, and 4 years respectively. As shown previously, development of GvHD was associated with a reduced risk of relapse in our data. In CML, a clear reduction of relapse risk occurred with hazard ratios declining proportionally to severity of both acute and chronic GvHD (Figure 1). The protective effect of severe acute (grade III-IV) GvHD was similar to that of extensive chronic GvHD, whereas the protective effect of mild acute (grade I-II) GvHD was comparable to that of limited extensive GvHD. ALL was almost equally sensitive to GvHD as CML, whereas MDS/MPN and lymphomas showed intermediate sensitivity (Figure 1). Acute and limited chronic GvHD were only associated with modest reductions in relapse risk in AML and PCD. The limited sensitivity of PCD to allo-immune effects was also evident in Kaplan-Meier curves of disease-free survival where – in contrast to other diseases – no plateau developed during follow-up (Figure 2, upper panel). Similarly, hazard rates of disease relapse failed to drop to values near zero in patients with PCD (Figure 2, lower panel). Interestingly, despite a comparatively poor association of GvHD and relapse in AML patients, a plateau in the survival curve occurred and hazard rates dropped in parallel to other diseases, suggesting that curative GvL effects operating independently of GvHD might occur in this disease. Discussion: These data confirm earlier observations of a potent GvL effect associated with GvHD. While GvHD and GvL are significantly associated in all diseases, the strength of this association strongly differs between disease entities (strongest correlation in CML and ALL, weakest correlation in AML and PCD). A poor correlation might point to either insensitivity of a particular disease to GvL effects, to GvL effects operating in the absence of and independent from GvHD, or to a significant fraction of patients already cured before allogeneic SCT. Disclosures: No relevant conflicts of interest to declare.
29
Eiselt, Anne-Kathrin, and Andreas Nieder. "Rule Activity Related to Spatial and Numerical Magnitudes: Comparison of Prefrontal, Premotor, and Cingulate Motor Cortices." Journal of Cognitive Neuroscience 26, no. 5 (May 2014): 1000–1012. http://dx.doi.org/10.1162/jocn_a_00545.
Full textAbstract:
In everyday situations, quantitative rules, such as “greater than/less than,” need to be applied to a multitude of magnitude comparisons, be they sensory, spatial, temporal, or numerical. We have previously shown that rules applied to different magnitudes are encoded in the lateral PFC. To investigate if and how other frontal lobe areas also contribute to the encoding of quantitative rules applied to multiple magnitudes, we trained monkeys to switch between “greater than/less than” rules applied to either line lengths (spatial magnitudes) or dot numerosities (discrete numerical magnitudes). We recorded single-cell activity from the dorsal premotor cortex (dPMC) and cingulate motor cortex (CMA) and compared it with PFC activity. We found the largest proportion of quantitative rule-selective cells in PFC (24% of randomly selected cells), whereas neurons in dPMC and CMA rarely encoded the rule (6% of the cells). In addition, rule selectivity of individual cells was highest in PFC neurons compared with dPMC and CMA neurons. Rule-selective neurons that simultaneously represented the “greater than/less than” rules applied to line lengths and numerosities (“rule generalists”) were exclusively present in PFC. In dPMC and CMA, however, neurons primarily encoded rules applied to only one of the two magnitude types (“rule specialists”). Our data suggest a special involvement of PFC in representing quantitative rules at an abstract level, both in terms of the proportion of neurons engaged and the coding capacities.
30
EGAMI, Kazutaka, Syuuhei KUROKAWA, Toshirou DOI, and Osamu Ohnishi. "1004 Surface analysis by CMP pad conditioning." Proceedings of Conference of Kyushu Branch 2013.66 (2013): 321–22. http://dx.doi.org/10.1299/jsmekyushu.2013.66.321.
Full text
31
Orazov, M. R., E. S. Silantieva, R. A. Soldatskaya, and M. E. Belkovskaya. "The Efficacy of Physical Therapy in Treatment of Pelvic Floor Distress in Women of Reproductive Age." Doctor.Ru 19, no. 8 (2020): 71–76. http://dx.doi.org/10.31550/1727-2378-2020-19-8-71-76.
Full textAbstract:
Study Objective: To compare the efficacy of two physical therapy techniques in the treatment of pelvic floor distress (PFD). Study Design: This was a prospective, randomized, double-blind, controlled study. Materials and Methods: Health information about ninety-five women who had had vaginal delivery and suffered from PFD was reviewed in the study. In Group I (n = 50) patients were treated using high-intensity focused electromagnetic (HIFEM) technology, and in Group II (n = 45) electrical stimulation therapy was delivered via an intracavity sensor. Assessments in the study included physical examination, instrumental investigations, and a discussion with patients (completion of a questionnaire and a scale-based assessment). To establish reference values for the parameters used in the study, a control group was made up of 30 apparently healthy women who had had a vaginal delivery. Study Results: Ultrasound of the pelvic floor showed that in Groups I and II the anteroposterior diameter of the levator hiatus (LH) decreased by 3.12 mm and 1.16 mm, respectively (2.7-fold difference), and the transverse diameter of the LH decreased by 3.04 mm and 1.04 mm (2.9-fold difference). The area of the LH decreased by 1.38 cm2 in Group I and 0.08 cm2 in Group II. After treatment the mean Pelvic Floor Distress Inventory (PFDI-20) score was 1.9 times lower (p<0.001) in Group I and the number of women who reported a feeling of looseness in the vagina and urinary incontinence using a bimodal scale for complaint assessment was 1.5 and 1.9 times lower, respectively, than in Group II. Conclusion: Electromagnetic stimulation demonstrated higher efficacy than stimulation via an intracavitary sensor in the treatment of PFD. Keywords: pelvic floor distress, genital prolapse, high-intensity focused electromagnetic stimulation.
32
LIEW, K. W., and N. S. M. EL-TAYEB. "THE EFFECT OF ROTOR DISC MATERIAL ON TRIBO BEHAVIOR OF AUTOMOTIVE BRAKE PAD MATERIALS." Surface Review and Letters 15, no. 05 (October 2008): 625–33. http://dx.doi.org/10.1142/s0218625x08011925.
Full textAbstract:
This work aims to investigate the effect of two different counterdisc materials, i.e. gray cast iron (GCI) and ductile gray cast iron (DGCI) on tribo behavior of non-commercial frictional materials (NF1, NF2, NF4, and NF5) and two other chosen commercial brake pads (CMA and CMB) under dry sliding contact conditions. The four non-commercial frictional materials were fabricated with various percentages of phenolic binder resin (15 and 20 vol.%) and reinforced with steel fibers (15 and 20 vol.%) using hot press molding methods. Tribo tests were carried out using a small-scale tribo-tester of pad-on-disc type. Friction coefficient and wear of non-commercial and commercial brake pads were measured against each counterdisc (GCI and DGCI) and compared. Then, the friction and wear characteristic are discussed by comparing the experimental results obtained for each kind of cast iron. The results showed that maximum friction coefficient (0.4–0.5) of brake pad was attained at 2.22 MPa applied pressure and 2.1 m/s sliding speed when the frictional brake pad materials were tested against DGCI disc rotor. Meanwhile, similar wear rates for all frictional brake pad materials were sustained at higher applied pressure and sliding speed when tested against either type of rotor discs (GCI and DGCI). The results on the other hand, indicated that non-commercial materials NF1 and NF4, gave better wear resistance compared to other frictional pad materials. NF2 exhibited the lowest wear resistance when tested against GCI and DGCI rotor disc at all applied pressure and sliding speeds. The latter result is referred to the low percentage binder resin in the friction material NF2.
33
Millot, Frédéric, Joelle Guilhot, Meinolf Suttorp, Anne Sophie Meunier, Gunes Adalet Meral, Petr Sedlacek, Eveline de Bont, et al. "Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)." Blood 126, no. 23 (December 3, 2015): 1576. http://dx.doi.org/10.1182/blood.v126.23.1576.1576.
Full textAbstract:
Abstract Aims: To determine in children and adolescents with chronic myeloid leukemia (CML) in chronic phase (CP) treated with imatinib front line, (i) the probability of switch to a second line therapy, (ii) to characterize the reasons and the type of switch and (iii) to determine the impact of the switch on outcome. Methods: Children and adolescents (<18 years) with CML diagnosed later than the year 2000 and enrolled in the international registry for childhood CML (I-CML-Ped Study) were the subjects of the study. Results: The I-CML-Ped study enrolled 301 children and adolescents with CML in CP treated with imatinib front line. Among them 112 patients subsequently switched to a second line therapy (median duration of imatinib treatment before the switch: 16 months [range: 1-111]).The probability of switch at 38 months was 50% (95% CI: 29-60). Primary resistance was the cause of switch in 47% of the patients: failure to achieve complete hematologic response (CHR, 1%), complete cytogenetic response (CCR, 20%) or major molecular response (MMR, 24%); not detailed (2%). A loss of response (CHR loss [2%] or CCR loss [4%] or MMR loss [13%]) or progression were the cause of switch in 19% and 4% of the patients, respectively. Occurrence of non hematologic toxicity (mainly muscle-skeleton pain) was the cause of switch in 10% of the patients. The reason of switch was the physician's choice in 20% of the patients (switch to hematopoietic stem cell transplantation [HSCT] while the patients were in MMR or deeper molecular response). The second line therapy consisted of second generation tyrosine kinase inhibitors (63%), chemotherapy (4%) or HSCT (33%). With a median follow up of 38 months (range: 2-150), overall, 8 deaths were recorded among switching patients: all were patients transplanted for acute phase (4 patients), hematologic resistance (1 patient), loss of hematologic response (1 patient) or physician's choice (2 patients). The causes of death were treatment related mortality (7 patients) and relapse (1 patient). One death only was recorded among the non switching patients. The probability of overall survival at 48 months was 90% (95% CI: 81% - 95%) for switching patients and 98% (95% CI: 89% - 100%) (p=0.005) for the non switching patients. Conclusion: Treatment failure is the main reason for a switch to a second line therapy in children and adolescents treated with imatinib front line. Efficacy of second line therapy still needs improvement. Disclosures No relevant conflicts of interest to declare.
34
Liu, Zhuo, Yong Wang, Leo Yu Zhang, and Jun Ma. "A Novel Compressive Image Encryption with an Improved 2D Coupled Map Lattice Model." Security and Communication Networks 2021 (April 9, 2021): 1–21. http://dx.doi.org/10.1155/2021/6625579.
Full textAbstract:
The digital image, as the critical component of information transmission and storage, has been widely used in the fields of big data, cloud and frog computing, Internet of things, and so on. Due to large amounts of private information in the digital image, the image protection is fairly essential, and the designing of the encryption image scheme has become a hot issue in recent years. In this paper, to resolve the shortcoming that the probability density distribution (PDD) of the chaotic sequences generated in the original two-dimensional coupled map lattice (2D CML) model is uneven, we firstly proposed an improved 2D CML model according to adding the offsets for each node after every iteration of the original model, which possesses much better chaotic performance than the original one, and also its chaotic sequences become uniform. Based on the improved 2D CML model, we designed a compressive image encryption scheme. Under the condition of different keys, the uniform chaotic sequences generated by the improved 2D CML model are utilized for compressing, confusing, and diffusing, respectively. Meanwhile, the message authentication code (MAC) is employed for guaranteeing that the encryption image be integration. Finally, theoretical analysis and simulation tests both demonstrate that the proposed image encryption scheme owns outstanding statistical, well encryption performance, and high security. It has great potential for ensuring the digital image security in application.
35
Millot, Frédéric, Joelle Guilhot, Meinolf Suttorp, Adalet Meral Güneş, Petr Sedlacek, Evelina S. De Bont, Chi Kong Li, et al. "Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score." Blood 128, no. 22 (December 2, 2016): 626. http://dx.doi.org/10.1182/blood.v128.22.626.626.
Full textAbstract:
Abstract The Sokal score for patients less than 45 years can be used for the prognostic discrimination in the pediatric population. Limited data are available regarding the utility of the EUTOS score in the pediatric population (Gurrea Salas et al, Ann Hematol 2015). Recently, a new EUTOS score, the EUTOS Long Term Survival (ELTS) score was validated in the adult population (Pfirrmann et al, Leukemia 2016). The international registry for chronic myeloid leukemia (CML) in children and adolescents (I-CML- Ped Study registered at www.clinicaltrials.gov as NCT01281735) gave us the opportunity to test this score in this population. Aim: The aim of this analysis was the comparison of risk groups allocations and outcome between the Sokal (<45 years) score and the ELTS score in the pediatric population. Patients and Methods: As of June 1, 2016, 462 children and adolescents less than 18 years old were enrolled in the I-CML-Ped study between January 2011 and April 2016. Among them, 350 patients diagnosed with CML in chronic phase according to the ELN definition and treated with imatinib (+/- hydroxyurea or anagrelide) as first line treatment were eligible for analysis. For progression free survival (PFS) analyses, events of interest included progression to accelerated phase or blast crisis and deaths irrespective of its cause, whichever came first. For survival analyses, the event of interest was death from CML, deaths from other causes being considered as competing events, as initially designed in the ELTS score model. Estimates were compared by the log-rank test and Gray test respectively. Level of significance was 0.05. Results: The median follow up of the 350 patients was 3 years (range 1 month to 6 years). Progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year PFS was 92% (95% CI: 88%-94%) and the 5-year survival accounting for CML death was 97% (95% CI: 94%-99%). Of the 308 patients allocated to low (n=54), intermediate (n=118) and high (n=136) risk groups by the Sokal (<45 years) score, events (progression and/or deaths) occurred in 5.5%, 5% and 9.5%, respectively. Estimation of the 5-year progression free survival accounting for CML death according to these 3 risk groups was 93% (95% CI:81%-98%), 94% (95% CI: 87%-97%) and 88% (95% CI: 80%-93%), respectively (p = 0.376, overall). Estimation of the 5- year survival accounting for CML death according to these 3 risk groups was 100%, 97% (95% CI: 92%-100%) and 96% (95% CI: 89%-100%), respectively, (p = 0.576, overall). Of the 308 patients allocated to low (n=199), intermediate (n=68) and high (n=41) risk groups by the ELTS score, events (progression and/or deaths) occurred in 6%, 8.8% and 24%, respectively. Differences in PFS according to these risk groups were highly significant (p < 0.0001, overall) (Figure 1). Estimation of the 5-year PFS according to these 3 risk groups was 96% (95% CI:92%-98%), 94% (95% CI: 76%-95%) and 67% (95% CI: 49%-82%), respectively. Estimation of the 5-year survival related with CML death according to these 3 risk groups was 99% (95% CI:95%-100%), 96% (95% CI: 88%-99%) and 89% (95% CI: 10%-98%), respectively (p = 0.107, overall). Conclusion: ELTS score showed better differentiation regarding progression free survival than Sokal (<45 years) score in children and adolescents with CML. However , ELTS score has failed to predict the survival accounting for CML death only. A specific prognostic score incorporating clinical, biological and molecular features is still needed for the pediatric population. Figure 1. Figure 1. Disclosures Suttorp: Novartis, Bristol Meyer Squib, Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Biondi:BMS: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Cellgene: Other: Advisory Board.
36
Kanatli, Ulunay, Haluk Yetkin, Aykin Simsek, Koksal Besli, and Akif Ozturk. "The Relationship of the Heel Pad Compressibility and Plantar Pressure Distribution." Foot & Ankle International 22, no. 8 (August 2001): 662–65. http://dx.doi.org/10.1177/107110070102200808.
Full textAbstract:
Loss of heel pad elasticity has been suggested as one of the possible explanations of heel pain. This study aimed to determine the effect of heel pad thickness and its compressibility to heel pressure distribution, in 47 (94 feet) normal subjects and 59 (94 feet) patients with heel pain, using radiological measurements and EMED-SF (Novel, Munich) plantar pressure distribution measurement system. Both heels of the patients and control group were radiographed with and without weight bearing. The ratio of the heel pad thickness in loading to unloading position was defined as “the heel pad compressibility index.” The plantar peak pressure of the heel was measured at heel strike phase of the gait cycle. The compressibility index for control and patient groups were found to be 0.60 and 0.69, respectively. The peak pressure under the heel pad was recorded to be 28.4 N/cm2 for patients and 31.7 N/cm2 for control group. No significant difference was found for heel pad compressibility index and heel pad pressures between patient and control groups (p>0.05). This study revealed that there is no relationship between heel pad compressibility and pressure distribution of the heel pad both in control and patient group. We feel the flexibility of the heel pad does not have any influence on heel pain syndromes.
37
Masiuk, D., A. Sosnitskiy, A. Kokarev, and S. Koliada. "Експериментальне зараження поросят вірусом епідемічної діареї свиней." Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies 19, no. 77 (March 17, 2017): 208–13. http://dx.doi.org/10.15421/nvlvet7745.
Full textAbstract:
There were infected neonatal piglets in the first days of their lives PED virus suspension derived from pigs previously PED patients. Diagnosis for PED in piglets donor virus PED was inserted complex method for clinical and epizootic performance and confirmed the identification PEDV by PCR-RT using the test system «EZ-RED/TGE/PDCoV MPX 1.0 Real time RT-PCR» company Tetracore (USA) Thermocyclers CFX 96 Real-Time System company BIO RAD (USA). Homogenate small intestine of pigs PEDV donor, prepared in a blender for PCR in a thick band of 18 animal carcasses, frozen at -18 °C without cryopreservation and kept 359 days. Before infecting pigs and strip defrost by RT-PCR identified the concentration of the virus genome equivalents (GE) without establishing viable virions quantitative pathogen. For Sample 20 selected analog neonatal piglets, divided them into 3 experimental groups (group 1 – 5 piglets, group 2 – 5 piglets and group 3 – 7 piglets) and one control (3 piglets). Research pigs infected per os virus-containing suspension with a concentration PEDV 1.03×106 GE/cm3. The dose for infection first group was 6 cm3 (6.18×106 GE/cm3), for the second – 5 cm3 (5,15 × 106 GE/cm3), for the third – 4 cm3 (4.12 GE×106/cm3) homogenate. The fourth group – control (not infected). All the pigs were in identical conditions that fully meet the physiological needs of the body. Of the 17 infected pigs only 2 was infected PEDV. PED was confirmed by laboratory methods. In bacteriological examination of internal organs of pigs that came out of a research experiment and control group were diagnosed colibacteriosis. In the control group was isolated from heart and intestinal non-pathogenic for white mice E. coli. From pigs 1 and 2 research groups has been allocated to white mice nonpathogenic E. coli, is set colibacteriosis; 2 experimental group found in one pig hemolytic E. coli; 3 experimental group from the internal organs of pigs in conjunction with non-pathogenic for mice intestinal former cane isolated Klesiella spp., is diagnosed with mixed infection (E. coli, Klesiella spp.). From the intestine of experimental and control pigs do not identified beneficial microflora – aerococcus, lactobacteria, bifidobacteria and cultured putrefactive anaerobic spore facultative and non spore microflora.
38
Patel, Sagar S., Kwang Woo Ahn, Manoj Khanal, Caitrin Fretham, Celalettin Ustun, Betty K. Hamilton, Navneet S. Majhail, et al. "Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study." Blood 136, Supplement 1 (November 5, 2020): 7–8. http://dx.doi.org/10.1182/blood-2020-140503.
Full textAbstract:
Introduction Early non-infectious pulmonary toxicity (NIPT) is a significant HCT complication and comprises diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), and cryptogenic organizing pneumonia (COP) with an overall incidence ranging 1-10%. Treatment options are primarily immunosuppressive therapy and supportive care with limited efficacy. Mortality in IPS, for example, approaches 60-80% (PMID: 21531955). Therefore, to better identify potentially high-risk patients (pts) we performed a registry-based analysis of the incidence, risk factors, and outcomes of early NIPT after HCT. Methods This retrospective study included adult pts undergoing allogenic HCT for hematologic malignancies and non-malignant disorders as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) (2008-2017). Data analyses were divided into four common disease categories (AML/ALL, CML/MDS/MPN, NHL/CLL/PCD, and non-malignant diseases) to minimize statistical interactions in the multivariate model. The primary outcome was the incidence of and risk factors for individual NIPT and a composite of the three NIPT (IPS, DAH, COP); the secondary outcome was overall survival (OS). Multivariable Cox proportional hazards regression models were developed to identify the risk factors for NIPT and OS. In addition to baseline pre-transplant covariates, post-transplant neutrophil recovery (>500/mcL x 3 consecutive days), platelet recovery (>20k/mcL x 3 consecutive days, without transfusion in 7 previous days) and grade 2-4 acute GVHD were included as time-dependent covariates in the multivariable models. Results Characteristics of 21,587 adult pts are shown in Table 1. Median age at HCT was 54 years, 59% were male, and 39% had KPS <90. Median follow-up was 49 months. Per the HCT-Comorbidity Index (HCT-CI), 15% and 24% of pts had a severe (FEV1 and/or DLCO≤65%, dyspnea at rest, requiring supplemental oxygen) and moderate (FEV1 and/or DLCO 66-80%, dyspnea on slight activity) pulmonary comorbidity, respectively. Pre-transplant, 3% of pts had a history of mechanical ventilation, 5% had a history of pulmonary fungal infection, and 40% reported a smoking history. Most pts had a matched sibling or unrelated donor (68%) and received peripheral blood graft (71%). Myeloablative conditioning was used in 49% pts, and 39% received total body irradiation (TBI). Table 2 shows the cumulative incidence of early NIPT amongst pts in the four disease categories. Multivariable analysis in the AML/ALL group identified TBI-based conditioning, grade 2-4 acute GVHD, HCT-CI score of 1-3, and prior autologous HCT were associated with increased risk of NIPT, while platelet recovery decreased the risk of NIPT. In the CML/MDS/MPN group, smoking history, grade 2-4 acute GVHD and HCT-CI scores of 2-5+ were associated with increased risk of NIPT, while non-TBI and non-myeloablative TBI conditioning and platelet recovery were associated with a lower risk. In the NHL/HD/CLL/PCD group, a higher risk of NIPT was seen with severe pulmonary comorbidity pre-HCT and chronic GVHD, while platelet recovery and non-TBI regimens were associated with a lower risk. In the non-malignant disease group, both neutrophil and platelet recovery were associated with a lower risk of NIPT. Furthermore, the multivariable analysis for OS (Table 2) showed across all disease groups, NIPT increased the risk of mortality (vs. no NIPT; HR of 4.3 in AML/ALL, 4.1 in CML/MDS/MPN, 3.5 in NHL/CLL/PCD, 6.8 in non-malignant diseases; p<0.0001). Conclusions This large registry-based analysis of allogeneic HCT pts highlights several risk factors for the development of early NIPT including smoking history, severe pulmonary comorbidity, myeloablative TBI conditioning, and acute and/or chronic GVHD. Identification of these risk factors can enhance appropriate selection of pts prior to HCT. We also found that post-transplant, platelet and neutrophil recovery was associated with a reduced risk of NIPT. Furthermore, early NIPT is associated with a several-fold higher mortality risk in the current era despite significant advances in supportive care. Future studies are needed to optimize risk factors such as conditioning regimen and graft source selection to reduce the risk of early NIPT. Disclosures Ustun: Kadmon: Honoraria. Hamilton:Syndax Pharmaceuticals: Consultancy, Honoraria. Majhail:Anthem, Inc.: Consultancy; Incyte: Honoraria; Nkarta Therapeutics: Honoraria; Mallinckrodt: Honoraria. Sorror:Jazz Pharmaceutical: Other: Honorarium for Advisory role. . Stadtmauer:Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology: Consultancy. Pasquini:Bristol Myers Squibb: Consultancy; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Other; Novartis: Research Funding; Kite: Research Funding.
39
Milvita, Dian, Alimin Mahyudin, and Vinny Alvionita. "ANALISIS NILAI PERCENTAGE DEPTH DOSE(PDD) TERHADAP VARIASI KEDALAMAN TARGET DAN LUAS LAPANGAN PENYINARAN MENGGUNAKAN PESAWAT LINAC-CX." Komunikasi Fisika Indonesia 15, no. 2 (October 30, 2018): 93. http://dx.doi.org/10.31258/jkfi.15.2.93-97.
Full textAbstract:
Percentage Depth Dose (PDD) value measurement is done by varying the target depth and field size. The study was carried out with variations in target depth of 0 cm to 30 cm with 1 cm intervals and fields size ranging from (5x5) cm2 to (39x39) cm2 with intervals (2x2) cm2. PDD is a comparison of the radiation dose at a depth to the radiation dose at the maximum depth normalized by percentage. This study was also conducted to determine the value of radiation doses received by phantoms from the PDD measurement value. This research used 2 photon energy beam that is 6 MV and 10 MV. This study uses water phantom as a substitute for patients with radiation source technique Source Surface Distance (SSD). PDD measurements were performed using a chamber ionization detector. The results obtained showed that the number of radiation doses received by fantom increased to the maximum depth (zmax). After passing zmaks, the radiation dose received by the phantom has decreased. Likewise along with the increase in the amount of radiation field, the value of radiation doses received by phantoms will also increase.
40
Ueno, Kazuki, Nagisa Wada, Keiichi Kimura, and Khajornrungruang Panart. "K13 Study on Temperature Change of Wafer and Polishing pad in Chemical Mechanical Polishing." Proceedings of Conference of Kyushu Branch 2008.61 (2008): 353–54. http://dx.doi.org/10.1299/jsmekyushu.2008.61.353.
Full text
41
Kumar, Anil, Nupur Pruthi, B. Indira Devi, and Arun Kumar Gupta. "Response of Syrinx Associated with Chiari I Malformation to Posterior Fossa Decompression with or without Duraplasty and Correlation with Functional Outcome: A Prospective Study of 22 Patients." Journal of Neurosciences in Rural Practice 09, no. 04 (October 2018): 587–92. http://dx.doi.org/10.4103/jnrp.jnrp_10_18.
Full textAbstract:
ABSTRACT Background: The aim of the study is to correlate the surgical outcome with radiological changes in patients with Chiari I malformation (CMI) with syrinx. We also compared long-term functional and radiographic outcome in CM1 patients treated with posterior fossa decompression (PFD) with or without duroplasty. Patients and Methods: From December 2013 to October 2015, 22 patients who underwent surgery with the diagnosis of CMI and syrinx were included in the study. Measurements were performed on preoperative and postoperative magnetic resonance (MR) scans using the same software. All patients underwent PFD with or without duroplasty. Clinical results were evaluated on the basis of the Chicago Chiari Outcome Scale (CCOS). We assessed the degree of resolution of syrinx and outcome of Chiari decompression with PFD versus PFD with duroplasty. Mean duration of follow-up was 12.4 ± 5.37 months (range: 6–24 months). Results: Out of 19 patients in whom syrinx diameter decreased on postoperative MR imaging, 17 (89.5%) improved based on CCOS and 2 (10.5%) were unchanged while out of three patients in whom syrinx worsened, 2 (66.7%) improved and 1 (33.3%) was unchanged (P = 0.37). The cord diameter was found to have decreased in 12 patients and of these 11 (91.7%) improved. The cord diameter increased in 10 patients, but 8 (80%) improved (P = 0.57). The mean changes in syrinx, cord, and syrinx/cord ratio were studied in both groups with and without duroplasty, were not statistically significant. In this study, radiological parameters failed to predict functional outcome. Conclusions: The outcome does not correlate with change in any of the syrinx-related factors. Surgical decompression with or without duroplasty does not have a statistically significant relationship in the degree of syrinx resolution. Surgical decompression without duroplasty provides the benefits of surgical decompression while avoiding the complications of intradural techniques.
42
Kulikov, Sergey M., Olga Yu Vinogradova, Ekaterina Yu Chelysheva, Marya V. Galayko, Irina A. Titshenko, Eduard G. Gendgan, Olga M. Senderova, et al. "First Results of Russian Multicenter Population Base Study of the Incidence of Chronic Myeloid Leukemia." Blood 120, no. 21 (November 16, 2012): 4431. http://dx.doi.org/10.1182/blood.v120.21.4431.4431.
Full textAbstract:
Abstract Abstract 4431 The European Treatment Outcome Study (EUTOS) is register based international investigation started in June 2007. [1] The aim is to study the epidemiology of CML and to gain insight into the ‘real world’ treatment of patients with CML. Population base section (EUTOS-PBS) is the prospective study directed mostly to epidemiology aims. Russian part of the EUTOS-PBS registry collect data of newly diagnosed patients lived in 7 large regions of about 10 millions of population totally. EUTOS-PBS inclusion criteria are following: newly diagnosed CML (Ph +/BCR-ABL) started form 1st October 2009, age: older than 18. Russian CML group includes additional protocol for collection data for patients with clinical symptoms of CML. These patients are included into the roster table and after laboratory confirmation are enrolled into the main phase of the study. Thus, 174 patients were included in pre-phase, 142 (82%) had the diagnosis of CML which was confirmed by cytogenetic/molecular-genetic tests (Ph +/BCR-ABL +), 32 (18%) was not confirmed as CML. Among them 87% (n = 20) - have other Ph–negative chronic myeloproliferative diseases, and also acute leukemia (n = 1), cancer (n = 1), chronic inflammatory processes (n = 1). 142 patients with CML are 73 men, 69 women have the age from 18 to 82 (Me 49) years. 136 (96%) of patients are in the chronic phase, 6 (4%) -in the phase of acceleration, nobody in a blast ñrisis. The standard frequency analysis with adjustment to the standard population of WHO was carried out to estimate distribution. The results was presented in the table 1. As shown registered morbidity in 6 regions is not varied so much: source incidence is 0,58 (0,44–0,69); standardized on WHO incidence is: 0,7 (0,57 – 0,85); per 100 thousands per year. Estimated registered morbidity of CML in Russian regions are in 1.5–2 times less, than published morbidity in western countries. The analysis of the incidence in age stratums (table 2) shows that there is no much growth of age morbidity as expected. It obviously points to low detectability of new CML incidents in senior age categories (are more senior 60 years). This fact is probably the main reason of low total registered morbidity. Tabl.1. Incidence rate of new CML cases in 6 regions of Russia Region population (mln.) N CML for 100000. in year Standard of WHO Mordovia Republic 0.87 14 0.69 0.85 Kirov region 1.46 18 0.53 0.6 Perm territory 2.77 45 0.68 0.8 Bryansk region 1.35 17 0.53 0.65 Irkutsk region 2.55 36 0.56 0.68 Zabaikal's territory 1.36 12 0.44 0.57 Total 10.13 142 0.58 0.7 Table 2.CML incidence in age groups Age groups Male Female Maleandfemale 18–29 0.65 0.57 0.61 30–39 0.86 0.39 0.62 40–49 0.50 0.57 0.54 Conclusion: The CML incidence in Russia regions is underestimated. The main reason is an insufficient CML diagnostic screening in the senior age groups of population. References. 1. http://www.eutos.org/content/registry/documents/documents/e940/infoboxContent941/CML-Registry_February09.pdf Disclosures: Vinogradova: BMS: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau. Chelysheva:Novartis Pharma: Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau; MSD: Speakers Bureau. Senderova:Novartis: Consultancy. Turkina:Novartis Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.
43
Motiur Rahman, M Shamsuzzaman, Manoshi Sarker, Abdul Jobber, Mohsin Mia, Asish Kumar Bairagi, Musfika Ahmed, et al. "Dosimetric characterization of medical linear accelerator Photon and Electron beams for the treatment accuracy of cancer patients." World Journal of Advanced Engineering Technology and Sciences 3, no. 1 (August 30, 2021): 041–59. http://dx.doi.org/10.30574/wjaets.2021.3.1.0046.
Full textAbstract:
In radiotherapy treatment planning process, quality assessment (QA) is indispensable for achieving accuracy and avoidance of treatment errors. In this perspective, present study focused on the Photon and Electron beams characterization of a medical linear accelerator (LINAC) to ascertain dosimetric QA in Absolute and Reference dosimetry. In this connection, the beam outputs were investigated in terms of Dmax and Dw,max (dose at depth dmax) in absolute dosimetry for Photon and Electron beams, respectively. In accordance with the measured Dmax and Dw,max parameters, Photon and Electron beam outputs were standardized to ensure standard output of 1 cGy/MU. In reference dosimetry, the parametric evaluation was performed for dosimetric QA in terms of percent depth dose (PDD), beam profile flatness and symmetry, output factors: Scp, Sc, Sp with varying field size (FS) ranging from 4´4 cm2 to 40´40 cm2 normalized at FS 10´10 cm2 for the 6 MV and 10 MV Photon beams. The measured PDDs at 10 cm depth (D10) were found to be 66.8% and 73.6% for 6 MV and 10 MV Photon beams, respectively, with significantly small deviation of 1% and 0.8% in comparison with an international PDD protocol of British Journal of Radiology-25 (BJR -25). In the case of Electron beams characterization, PDD was verified with 10´10 cm2 cone/applicator, beam profile flatness and symmetry were analyzed at the field sizes ranging from 6´6 cm2 to 25´25 cm2 normalized at 10´10 cm2 cone/applicator, and Electron cone ratios were investigated for a given cone/applicator relative to the 15´15 cm2 one for the 6, 9, 12, 15 MeV Electron energies. The PDDs of all the Electron beams revealed reasonable consistency with manufacturer’s estimations of 90%, 80%, and 50% PDDs at various depths of ionization.
44
FUKUDA, Akira, and Masahito MITARAI. "10105 A Trial of Slurry Flow Visualization at Pad Asperity Scale in CMP." Proceedings of Conference of Kanto Branch 2015.21 (2015): _10105–1_—_10105–2_. http://dx.doi.org/10.1299/jsmekanto.2015.21._10105-1_.
Full text
45
Dancescu, M., M. Rubio-Trujillo, G. Biron, D. Bron, G. Delespesse, and M. Sarfati. "Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression." Journal of Experimental Medicine 176, no. 5 (November 1, 1992): 1319–26. http://dx.doi.org/10.1084/jem.176.5.1319.
Full textAbstract:
B chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of slow-dividing and long-lived monoclonal B cells arrested at the intermediate stage of their differentiation. We previously showed that interleukin 4 (IL-4) not only inhibits but also prevents the proliferation of B-CLL cells. We report here that IL-4 protects the B-CLL cells from death by apoptosis (programmed cell death [PCD]). IL-4 inhibits spontaneous and hydrocortisone (HC)-induced PCD of highly purified B cells from 12 unselected CLL patients, as shown by sustained cell viability and lack of DNA fragmentation. IL-1, -2, -3, -5, -6, -7, tumor necrosis factor alpha, and transforming growth factor beta have no protective effect. The in vitro rescue from apoptosis by IL-4 is reflected by an increased expression of Bcl-2 protein, a proto-oncogene directly involved in the prolongation of cell survival in vivo and in vitro. Hence, IL-4-treated B-CLL cells express significantly more Bcl-2 than unstimulated, HC-treated, or fresh B-CLL cells. Furthermore, subcutaneous injection of IL-4 into one CLL patient enhances Bcl-2 protein expression in the leukemic B cells. These data may suggest that IL-4 prevents apoptosis of B-CLL cells using a Bcl-2-dependent pathway. Given our recent observations that fresh T cells from B-CLL patients express IL-4 mRNA, we propose that IL-4 has an essential role in the pathogenesis of CLL disease, by preventing both the death and the proliferation of the malignant B cells.
46
Yui, Ryuji, Keiichi Kimura, Keisuke Suzuki, and Panart Khajornrungruang. "K24 Study on friction between wafer and polishing pad in CMP process." Proceedings of Conference of Kyushu Branch 2011.64 (2011): 397–98. http://dx.doi.org/10.1299/jsmekyushu.2011.64.397.
Full text
47
Aljamal, Mohammad. "Percentage depth dose (PDD) and Beam profile measurements using CT based MAGAT gel dosimetry system and Monte Carlo calculation." New Trends and Issues Proceedings on Advances in Pure and Applied Sciences, no. 7 (November 30, 2016): 102–7. http://dx.doi.org/10.18844/gjpaas.v0i7.3168.
Full textAbstract:
Abstract
The aim of this project is to develop and to evaluate the CT based MAGAT (methacrylic acid, gelatine and tetrakis phosphonium chloride) polymer gel dosimetry for measuring 3D dose distributions in radiation treatment. The MAGAT gel was prepared based on the formulation proposed in the literature. The percentage depth dose (PDD) and beam profile of 8 x 8 cm2 field size photon beam from a 6 MV linear accelerator were measured. Monte Carlo simulation was carried out to calculate PDD and beam profiles in the simulated MAGAT gel phantom to verify the data measured using MAGAT gel dosimetry for the 8 x 8 cm2 field size. The PDD and beam profile calculated using simulated MAGAT gel phantom agreed very well with that measured using MAGAT gel dosimetry. However, there were some differences between the simulated PDD with that measured at the surface region due to the electron contamination at the surface of the simulated phantom. In conclusion, the results showed that the CT based MAGAT gel dosimetry system is promising method to measure three- dimensional dose distribution based on PDD and Beam profile measurement.
Keywords: MAGAT gel, CT, Monte Carlo simulation
48
Hu, Xueyun, Chu Zeng, Jinling Su, Imran Khan, Ahmad Zada, and Ting Jia. "Overexpressing 7-Hydroxymethyl Chlorophyll a Reductase Alleviates Non-Programmed Cell Death during Dark-Induced Senescence in Intact Arabidopsis Plants." Biomolecules 11, no. 8 (August 3, 2021): 1143. http://dx.doi.org/10.3390/biom11081143.
Full textAbstract:
Leaf senescence, the last stage of leaf development, is a well-regulated and complex process for investigation. For simplification, dark-induced leaf senescence has frequently been used to mimic the natural senescence of leaves because many typical senescence symptoms, such as chlorophyll (Chl) and protein degradation, also occur under darkness. In this study, we compared the phenotypes of leaf senescence that occurred when detached leaves or intact plants were incubated in darkness to induce senescence. We found that the symptoms of non-programmed cell death (non-PCD) with remaining green coloration occurred more heavily in the senescent leaves of whole plants than in the detached leaves. The pheophorbide a (Pheide a) content was also shown to be much higher in senescent leaves when whole plants were incubated in darkness by analyses of leaf Chl and its metabolic intermediates. In addition, more serious non-PCD occurred and more Pheide a accumulated in senescent leaves during dark incubation if the soil used for plant growth contained more water. Under similar conditions, the non-PCD phenotype was alleviated and the accumulation of Pheide a was reduced by overexpressing 7-hydroxymethyl Chl a (HMChl a) reductase (HCAR). Taken together, we conclude that a high soil water content induced non-PCD by decreasing HCAR activity when whole plants were incubated in darkness to induce senescence; thus, the investigation of the fundamental aspects of biochemistry and the regulation of leaf senescence are affected by using dark-induced leaf senescence.
49
Giralt, Sergio, Brent Logan, Mei-Jei Zhang, Olivia McGaha, Karen Ballen, Christos Emmanouilides, Rajneesh Nath, et al. "Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation." Blood 104, no. 11 (November 16, 2004): 2751. http://dx.doi.org/10.1182/blood.v104.11.2751.2751.
Full textAbstract:
Abstract Purpose: Determine the current pattern of use of non-ablative and reduced intensity conditioning regimens (NST) with volunteer unrelated donor progenitor cell transplantation (URD-T) in patients with malignant diseases, and identify potential prognostic factors for transplant outcomes. Patients and Methods: The National Marrow Donor Program (NMDP) database was queried to identify adult patients (greater than 18 years old) who had undergone an URD-T from 01/01/94 until 05/31/01, had a malignant disorder and received a conditioning regimen which fulfilled one of the following criteria: 500 cGy or less of total body irradiation, 9 mg/kg or less of total busulfan dose; 140 mg/m2 or less total melphalan dose and included a purine analog (fludarabine, cladribine, or pentostatin). A total of 293 patients were available for analysis of which 38% had acute leukemia or MDS, 18% had CML or another myeloproliferative disorder (MPD), 33% had CLL or lymphoma and 11% had a plasma cell disorder (PCD). The following transplant outcomes were analyzed: acute and chronic graft versus host disease (GVHD), non-relapse mortality (NRM), overall survival (OS) and event free survival (EFS). Results: The number of URD-T performed as NST have increased for all disease categories. From 1995 to 1999, 24 transplants were performed for acute leukemia (AML, ALL and MDS); 13 for MPD; 25 for lymphoproliferative disorders (CLL and lymphoma) and 1 for PCD. In the year 2000 alone these increased to 56 transplants for acute leukemia, 53 for CLL or lymphoma, 30 for MPD and 20 for PCD. When compared to 7015 NMDP recipients of ablative allografts performed during the same time period, recipients of NST were older (52 vs. 32 years), were more likely to have undergone transplant in a disease phase other than CR1, CR2 or first Chronic Phase (79% vs. 51%) and were more commonly treated for NHL and AML. NST patients had received a prior transplant in 63% of cases, and 35% had a Karnofsky performance score (KPS) of < 90 prior to transplant. The incidence of Grade II-IV acute GVHD for the whole group was 39% ± 5%. The 100 day and 1 year NRM rates were 20% ± 4% and 31% ± 5% respectively. Currently 83 patients are alive at a median of 985 days (range = 99–1825) with 77 patients free of progression. The 2 year OS and EFS rates are 33% ± 5% and 31% ± 5% respectively. On multivariate analysis favorable prognostic factors for OS were better HLA match, blood versus marrow stem cells and pre-transplant KPS ≥ 90%. Hazard Ratio 95% Confidence Intervals HLA Matching Match 1 Potential Match 4.701 3.097–7.136 Mismatch 2.128 1.509–3.001 Karnofsky Performance Scale < 90 1 ≥ 90 0.607 0.443–0.834 Stem Cell Source Peripheral Blood 1 Bone Marrow 1.602 1.151–2.229 Conclusions: URD-T with NST regimens are being performed more frequently, particularly in older patients. Although feasible and effective in a small fraction of patients, the procedure is still associated with significant morbidity and mortality. Factors relevant for outcomes after conventional myeloablative allografting (HLA match and performance status) remain important for outcomes after NST.
50
Park, Kihyun, Jaeyoung Choi, Jaewoo Jung, Jaehong Park, Masaharu Kinoshita, and Haedo Jeong. "A Study on Manufacture and Evaluation of CMP pad with Controllable Contact Area(Surface and edge finishing)." Proceedings of International Conference on Leading Edge Manufacturing in 21st century : LEM21 2005.3 (2005): 1211–15. http://dx.doi.org/10.1299/jsmelem.2005.3.1211.
Full text